Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Nicorandil suppressed myocardial purine metabolism during exercise in patients with angina pectoris

  • 23 Accesses

  • 1 Citations


To elucidate the effect of Nicorandil on myocardial energy metabolism and myocardial sympathetic activity, we administered Nicorandil orally to eight patients with angina pectoris prior to exercise testing. Arterial and coronary sinus levels of lactate, ammonia, hypoxanthine (HX), adrenaline and noradrenaline were measured during exercise in order to determine the irrespective myocardial extraction ratios (MER). Compared to placebo, Nicorandil increased the time to development of significant ST depression (322 vs 390 s) while decreasing the maximum amplitude of ST depression (0.244 vs 0.216 mV). Heart rate, systolic blood pressure, and the rate pressure product during exercise were not significantly affected. The MER of lactate, measured during exercise, was significantly higher after Nicorandil than placebo (13.6 vs 27.9). Similarly, the MERs of ammonia and HX were significantly higher after Nicorandil (-46.0 vs 7.4% and −47.0 vs 9.9% respectively). Nicorandil, had no apparent effect on myocardial sympathetic activity as the MERs of adrenaline and noradrenaline were essentially unaffected. We conclude that Nicorandil decreased myocardial ischaemia and suppressed myocardial accelerated purine metabolism (a marker of cellular energy metabolism) during exercise in patients with angina pectoris. This effect appears not to be related to myocardial sympathetic activity.

This is a preview of subscription content, log in to check access.


  1. 1.

    Preuss KC, Gross GJ, Brooks HL, Warltier DC (1985) Hemodynamic actions of nicorandil, a new antianginal agent, in the conscious dog. J Cardiovasc Pharmacol 7:709–714

  2. 2.

    Gross G, Pieper G, Farber NE, Warltier D, Hardman H (1989) Effects of nicorandil on coronary circulation and myocardial ischemia. Am J Cardiol 63:11J-17J

  3. 3.

    Gross GJ, Auchampach JA, Maruyama M, Warltier D, Pieper GM (1992) Cardioprotective effects of nicorandil. J Cardiovasc Pharmacol 20[Suppl 3]:S22-S28

  4. 4.

    Norman B, Sollevi A, Kaijser L, Jansson E (1987) ATP breakdown products in human skeletal muscle during prolonged exercise to exhaustion. Clin Physiol 7:503–509

  5. 5.

    Ketai LH, Simon RH, Kreit JW, Grum CM (1987) Plasma hypoxanthine and exercise Am Rev Respir Dis 136:98–101

  6. 6.

    Lowenstein JM, Tornheim K (1971) Ammonia production in muscle: the purine nucleotide cycle. Science 171:387–400

  7. 7.

    Mineo I, Kono N, Hara N, Shimizu T, Yamada Y, Kawachi M, Kiyokawa H, Wang YL, Tarui S (1987) Myogenic hyperuricemia: a common pathophysiologic feature of glycogenesis type III, V, and VII. N Engl J Med 317:75–80

  8. 8.

    Serruys PW, Suryapranata H, Piscione F, Harmsen E, Brand M, Feyter P, Hugenholtz PG, Jong JW (1989) Myocardial release of hypoxanthine and lactate during percutaneous transluminal coronary angioplasty. Am J Cardiol 63:45E-51E

  9. 9.

    He MX, Gorman MW, Roming GD, Sparks HV Jr (1992) Adenosine formation and myocardial energy status during graded hypoxia. J Moll Cell Cardiol 24:79–89

  10. 10.

    Smolenski RT, Suitters A, Yacoub M (1992) Adenine nucleotide catabolism and adenosine formation in isolated human cardiomyocytes. J Moll Cell Cardiol 24:91–96

  11. 11.

    Fox IH, Palella TD, Kelley WN (1987) Hyperuricemia: a marker for cell energy crisis. N Engl J Med 317:111–112

  12. 12.

    Ogino K, Kitamura H, Osaki S, Hisatome I, Miyakoda H, Matsumoto T, Noguchi N, Kinugawa T, Kotake H, Mashiba H (1993) Clinical significance of ammonia response during exercise in patients with congestive heart failure. Different implication from lactate response. J Am Coll Cardiol 21(Suppl):480A

  13. 13.

    Kosaka H, Hisatome I, Ogino K, Tanaka Y, Osaki S, Kitamura H, Omodani H, Matsumoto T, Miyakoda H, Kotake H, Mashiba H, Inoue A (1993) Excess purine degradation in muscle with chronic haemodialysis patients. Nephron 64:481–482

  14. 14.

    Ogino K, Kinugawa T, Noguchi N, Kitamura H, Matsumoto T, Miyakoda H Kotake H, Mashiba H. (1992) Suppression of sympathetic nervous system activity by Nicorandil during exercise. (1992) Gen Pharmacol 23:325–329

  15. 15.

    Andersson B, Blomström-Lundqvist C, Hedner T, Waagstein F (1991) Exercised hemodynamics and myocadial metabolism during long-term beta-blockade in severe heart failure. J Am Coll Cardiol 18:1059–1066

  16. 16.

    Borg GA (1982) Psychophysical bases of perceived exertion. Med Sci Sports Exercise 14:377–381

  17. 17.

    Kobayashi K, Hakuta T (1987) Effects of Nicorandil on coronary hemodynamics in ischemic heart disease: comparison with nitroglycerin, nifedipine, and propranolol. J Cardiovasc Pharmacol 10:S109-S115

  18. 18.

    Taira N (1989) Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 63:18J-24J

  19. 19.

    Weiss RG, Bottomley PA, Hardy CJ, Gerstenblith G (1990) Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N Engl J Med 323:1593–1600

  20. 20.

    Lamping A, Christensen CW, Pelc LR, Warltier DC, Gross GJ (1984) Effects of nicorandil and nifedipine on protection of ischemic myocardium. J Cardiovasc Pharmacol 6:536–542

  21. 21.

    Pieper GM, Gross GJ (1987) Salutary action of Nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate. Circulation 76:916–28

  22. 22.

    Darby TD, Sprouse JH, Walton RP (1958) Evaluation of sympathetic reflex effects on the inotropic action of nitroglycerine, quinidine, papaverine, aminophylline, and isoproterenol. J Pharmacol Exp Ther 122:386–395

  23. 23.

    Nakaya H, Schwaltz A, Millard RW (1983) Reflex chronotropic and inotropic of calcium channel-blocking agents in conscious dogs. Circ Res 52:302–311

  24. 24.

    Thomas JA, Marks BH (1978) Plasma norepinephrine in congestive heart failure. Am J Cardiol. 41:233–243

  25. 25.

    Cohn JN, Levine TB, Olivari MT, Garberg V, Tura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819–823

  26. 26.

    Swedberg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmely WW, Chatterjee K (1984) Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without heart failure. Am J Cardiol 54:783–786

  27. 27.

    Kinoshita M, Nishikawa S, Sawamura M, Yamaguchi S, Mitsunami K, Itoh M, Motomura M, Bito K, Mashiro I, Kawakita S (1986) Comparative efficacy of high-dose versus low-dose Nicorandil therapy for chronic stable angina pectoris. Am J Cardiol 58:733–738

  28. 28.

    Watts JA, Norris TA, London RE, Steenbergen C, Murphy E (1990) Effects of diltiazem on lactate, ATP, and cytosolic free calcium levels in ischemic hearts. J Cardiovasc Pharmacol 15:44–49

Download references

Author information

Correspondence to K. Ogino.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ogino, K., Osaki, S., Noguchi, N. et al. Nicorandil suppressed myocardial purine metabolism during exercise in patients with angina pectoris. Eur J Clin Pharmacol 48, 189–194 (1995). https://doi.org/10.1007/BF00198297

Download citation

Key words

  • Nicorandil
  • Myocardial ischaemia
  • myocardial purine metabolism
  • myocardial sympathetic activity
  • angina pectoris
  • ammonia
  • hypoxanthine